Antibody Engineering & Therapeutics

Date

Sunday, December 12 - Thursday, December 16, 2021

Location

San Diego, CA & Virtual

Attendee at Antibody Engineering & Therapeutics

Join us at the leading antibody engineering conference of the year. Discover the latest innovations in antibody discovery, cytokine engineering, drug conjugates, immunotherapy, machine learning, and much more. Learn directly from industry experts on how to overcome common challenges and launch your program to commercial success. Below you will find our involvement throughout the program. Visit booth #505 to meet with our experts and start a conversation around how we can add significant value to your therapeutic program.

Day 1: December 13, 2021

Discovery and Characterization of Nanobodies Directed Against SARS-COV2 Nucleocapsid For Use in Diagnostic Assays
Josie Corby, PhD, Principal Scientist at Abbott Diagnostics
Kathrin Zuberbühler, PhD, Associate Director, Antibody Engineering at Charles River

Day 2: December 14, 2021

High-Throughput Antibody Discovery and Engineering: Driving Innovation Towards 0-day Discovery Sessions
Jean-Philippe Bürckert, PhD, Director, Bioinformatics, Large Molecule Discovery at Charles River

Determining the Specificity of Biotherapeutics to Avoid Off-target Liabilities
Brad Gartland, Senior Client Manager at Charles River

Scientific Posters

End-to-end Discovery to Support the Development of Safe and Efficacious Engineered Cell Therapies | Kathrin Zuberbühler, PhD, Associate Director, Antibody Engineering at Charles River

Rapid Discovery on Hard Targets Combined with Fine-grained Engineering and OptimizationJean-Philippe Burckert, PhD, Director of Bioinformatics at Charles River

Where and What Off-target Assessments Using Tissue Cross-reactivity (TCR) and Retrogenix Cell Microarray Technologies | Nick Brown, Senior North American Business Development Manager at Charles River

Are you interested in meeting with one of our expert scientists? Complete the form to the right, and we’ll be in touch with scheduling options.